arrow_back Back Filing freshness 20-F Q4 FY2025 SEC EDGAR

QIAGEN N.V.

QGEN
$42.27 ▲ +0.55 (+1.32%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
19 Visible periods
7 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Bullish
auto_awesome

Analytical Summary

QIAGEN N.V. shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC
FCF / Share
Trailing P/E
Price / Book
FCF Yield
Debt / Equity 0.44
info Valuation on last close. End-of-day price, Aug 7, 2026.

19-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Long-Term Debt Long-term obligations
$1.65B
↑ +18.9%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
81
Returns
71
Financial Health
71
Cash Quality
68

Dividend History

Dividend / share · sourced from SEC filings
$0.25 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 19 quarters